{
    "Clinical Trial ID": "NCT00182767",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1",
        "  Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days",
        "  ixabepilone: Given IV",
        "  pegylated liposomal doxorubicin hydrochloride: Given IV",
        "INTERVENTION 2: ",
        "  Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2",
        "  Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days",
        "  ixabepilone: Given IV",
        "  pegylated liposomal doxorubicin hydrochloride: Given IV"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed diagnosis of 1 of the following: advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer (phase I and II) or metastatic breast cancer (phase I only).",
        "  Platinum- and taxane-resistant disease, defined as a disease-free interval of < 6 months after completion of platinum- and taxane-based chemotherapy. Disease progression during the regimen (phase II) or previously treated with >= 2 prior regimens for metastatic breast cancer, including 1 taxane-based regimen in the adjuvant or metastatic setting (phase I).",
        "  Meets 1 of the following criteria: Previously treated with a standard course of taxane- and platinum-based chemotherapy for ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer, that is platinum-refractory or -sensitive disease (phase I );",
        "  Measurable or evaluable disease, meeting 1 of the following criteria: unidimensionally measurable lesion, known disease and CA 125 > 50 U/mL on 2 occasions >= 1 week apart or known disease and CA 27-29, CA 15-3, or CA 125 > 50 U/mL on 2 occasions >= 1 week apart (for breast cancer patients)",
        "  ECOG 0-2 or Karnofsky 60-100%",
        "  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered.",
        "  At least 1 week since prior chemotherapy if given on a daily or weekly schedule and recovered.",
        "  At least 3 weeks since prior radiotherapy and recovered.",
        "  Recovered for more than 4 weeks from all adverse events related to prior agents.",
        "  Normal organ function including:",
        "  Normal bilirubin",
        "  WBC >= 3,000/mm3",
        "  Absolute neutrophil count >= 1,500/mm3",
        "  Platelet count >= 100,000/mm3",
        "  AST and ALT =< 2.5 times upper limit of normal (ULN)",
        "  Creatinine =< 1.5 times ULN or Creatinine clearance  60 mL/min",
        "Exclusion criteria:",
        "  No other concurrent investigational agents.",
        "  No concurrent combination antiretroviral therapy for HIV-positive patients.",
        "  No other concurrent anticancer therapy.",
        "  Has received a previous chemotherapy regimen for this cancer that included drugs such as docetaxel or paclitaxel.",
        "  Life expectancy of more than 3 months",
        "  No symptomatic congestive heart failure",
        "  No unstable angina pectoris",
        "  No cardiac arrhythmia",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception",
        "  No history of allergic reaction attributed to compounds of similar chemical or biological composition to Cremophor\u00ae or study drugs",
        "  No neuropathy >= grade 2",
        "  No ongoing or active infection",
        "  No psychiatric illness or social situation that would preclude study compliance.",
        "  No other uncontrolled illness.",
        "  No active brain metastases, including any of the following: evidence of cerebral edema by CT scan or MRI, evidence of disease progression on prior imaging studies, requirement for steroids or clinical symptoms of brain metastasis."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I)",
        "  Dose-Limiting Toxicities are assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events classification and usually encompasses all grade 3 or higher toxicities",
        "  Time frame: 28 days",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1",
        "  Arm/Group Description: Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days",
        "  ixabepilone: Given IV",
        "  pegylated liposomal doxorubicin hydrochloride: Given IV",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  1",
        "Results 2: ",
        "  Arm/Group Title: Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2",
        "  Arm/Group Description: Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days",
        "  ixabepilone: Given IV",
        "  pegylated liposomal doxorubicin hydrochloride: Given IV",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/6 (100.00%)",
        "  Anemia1/6 (16.67%)",
        "  Constipation1/6 (16.67%)",
        "  Mucositis1/6 (16.67%)",
        "  Vomiting0/6 (0.00%)",
        "  Dehydration0/6 (0.00%)",
        "  Abdominal pain0/6 (0.00%)",
        "  Small intestinal obstruction0/6 (0.00%)",
        "  Nausea0/6 (0.00%)",
        "  Ascites0/6 (0.00%)",
        "  Diarrhea0/6 (0.00%)",
        "  Fatigue0/6 (0.00%)",
        "  Death NOS1/6 (16.67%)",
        "  Infection with grade 3 or 4 neutrophils0/6 (0.00%)",
        "Adverse Events 2:",
        "  Total: 6/6 (100.00%)",
        "  Anemia0/6 (0.00%)",
        "  Constipation0/6 (0.00%)",
        "  Mucositis2/6 (33.33%)",
        "  Vomiting1/6 (16.67%)",
        "  Dehydration1/6 (16.67%)",
        "  Abdominal pain0/6 (0.00%)",
        "  Small intestinal obstruction0/6 (0.00%)",
        "  Nausea0/6 (0.00%)",
        "  Ascites0/6 (0.00%)",
        "  Diarrhea0/6 (0.00%)",
        "  Fatigue0/6 (0.00%)",
        "  Death NOS0/6 (0.00%)",
        "  Infection with grade 3 or 4 neutrophils1/6 (16.67%)"
    ]
}